Population screening programmes temporarily on hold Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.
Antimicrobial resistance in the Netherlands is remaining reasonably stable Antimicrobial resistance is increasing on a global level. It is difficult to treat infections caused by resistant bacteria.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Meningococcal type W most notable infectious disease in 2017 The report ‘State of Infectious Diseases in the Netherlands in 2017’ published by RIVM today, provides an overview of the most important developments in infectious diseases in the Netherlands and a
Meningococcal disease serious, but still rare Meningococcal disease is a disease caused by a bacterium, the meningococcus. There are several types of this bacterium. In most cases, it does not make you ill.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
Integrated approach reduces harmful effects of medicines in surface waters Residues of medicinal products, such as painkillers, hormones and antidepressants, are increasingly detected in surface water and drinking water.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.
Broad approach needed against pharmaceutical residues in environment We can all help to reduce pollution of the environment by pharmaceutical residues.